HC Wainwright Issues Pessimistic Outlook for Geron Earnings

Geron Co. (NASDAQ:GERN - Free Report) - Equities researchers at HC Wainwright dropped their Q3 2025 earnings per share estimates for Geron in a research note issued on Wednesday, May 7th. HC Wainwright analyst E. Bodnar now forecasts that the biopharmaceutical company will post earnings per share of ($0.03) for the quarter, down from their previous estimate of ($0.02). HC Wainwright currently has a "Neutral" rating on the stock. The consensus estimate for Geron's current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Geron's Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.13) EPS, FY2026 earnings at ($0.11) EPS and FY2027 earnings at ($0.04) EPS.

GERN has been the subject of several other reports. Needham & Company LLC restated a "buy" rating and set a $5.00 price target on shares of Geron in a research report on Wednesday, March 12th. Scotiabank cut Geron from a "sector outperform" rating to a "sector perform" rating and reduced their price objective for the company from $4.00 to $1.50 in a research note on Thursday, May 8th. Stifel Nicolaus cut their price target on Geron from $8.00 to $4.00 and set a "buy" rating on the stock in a research note on Thursday, February 27th. Barclays restated an "overweight" rating and issued a $4.00 price target (down from $9.00) on shares of Geron in a research note on Thursday, February 27th. Finally, B. Riley cut Geron from a "buy" rating to a "neutral" rating and cut their price target for the company from $3.50 to $2.00 in a research note on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Geron has an average rating of "Moderate Buy" and an average price target of $5.06.

Geron Trading Up 1.2%

Shares of GERN traded up $0.02 during midday trading on Monday, hitting $1.23. 1,774,057 shares of the stock were exchanged, compared to its average volume of 11,546,331. Geron has a 52-week low of $1.17 and a 52-week high of $5.34. The stock has a fifty day simple moving average of $1.45 and a 200 day simple moving average of $2.66. The firm has a market cap of $780.22 million, a P/E ratio of -3.83 and a beta of 0.76. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89.

Geron (NASDAQ:GERN - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.01. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The company had revenue of $39.60 million during the quarter, compared to analyst estimates of $49.88 million. During the same period in the prior year, the business posted ($0.07) earnings per share. The firm's revenue for the quarter was up 12927.3% compared to the same quarter last year.

Hedge Funds Weigh In On Geron

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Rovin Capital UT ADV grew its holdings in shares of Geron by 26.9% during the fourth quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company's stock worth $61,000 after buying an additional 3,660 shares during the last quarter. Xponance Inc. grew its holdings in shares of Geron by 12.9% during the fourth quarter. Xponance Inc. now owns 42,401 shares of the biopharmaceutical company's stock worth $150,000 after buying an additional 4,829 shares during the last quarter. KBC Group NV grew its holdings in shares of Geron by 45.1% during the fourth quarter. KBC Group NV now owns 24,414 shares of the biopharmaceutical company's stock worth $86,000 after buying an additional 7,592 shares during the last quarter. SBI Securities Co. Ltd. purchased a new position in shares of Geron during the fourth quarter worth about $28,000. Finally, Lazari Capital Management Inc. grew its holdings in shares of Geron by 11.7% during the fourth quarter. Lazari Capital Management Inc. now owns 76,424 shares of the biopharmaceutical company's stock worth $271,000 after buying an additional 8,000 shares during the last quarter. Hedge funds and other institutional investors own 73.71% of the company's stock.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.